Kailera Therapeutics (NASDAQ:KLRA) Shares Up 7.9% – What’s Next?

Shares of Kailera Therapeutics, Inc. (NASDAQ:KLRA) rose 7.9% during trading on Tuesday . The company traded as high as $16.69 and last traded at $16.62. 185,957 shares changed hands during mid-day trading, a decline of 74% from the average daily volume of 720,033 shares. The stock had previously closed at $15.40.

Wall Street Analyst Weigh In

KLRA has been the topic of several recent analyst reports. JPMorgan Chase & Co. began coverage on shares of Kailera Therapeutics in a research note on Tuesday, May 12th. They set an “overweight” rating and a $30.00 price objective on the stock. Leerink Partners began coverage on shares of Kailera Therapeutics in a research note on Tuesday, May 12th. They issued an “outperform” rating and a $36.00 target price for the company. Wall Street Zen cut Kailera Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. William Blair began coverage on Kailera Therapeutics in a research report on Tuesday, May 12th. They set an “outperform” rating on the stock. Finally, Jefferies Financial Group assumed coverage on Kailera Therapeutics in a research report on Tuesday, May 12th. They set a “buy” rating and a $48.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $42.75.

Kailera Therapeutics Trading Up 10.1%

The business’s 50 day simple moving average is $18.94. The firm has a market cap of $2.20 billion and a price-to-earnings ratio of -0.00.

Kailera Therapeutics (NASDAQ:KLRA) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.35). Equities research analysts expect that Kailera Therapeutics, Inc. will post -3.89 EPS for the current fiscal year.

Institutional Trading of Kailera Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. California State Teachers Retirement System acquired a new position in Kailera Therapeutics in the 2nd quarter valued at about $309,000. Frazier Life Sciences Management L.P. bought a new position in Kailera Therapeutics in the 2nd quarter valued at about $24,233,000. Wellington Management Group LLP acquired a new stake in Kailera Therapeutics during the second quarter worth approximately $64,308,000. Finally, Atlas Venture Life Science Advisors LLC acquired a new position in shares of Kailera Therapeutics in the second quarter valued at approximately $113,923,000.

Kailera Therapeutics Company Profile

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.